Now Playing
Opinion|Videos|May 29, 2024
Harnessing the Power of VR for Visual Field Testing: Results of The NOVA Trial
Author(s)Lorraine Provencher, MD
Lorraine Provencher, MD, reviews the NOVA trial which measured and validated the sensitivity of a novel VR-based wearable headset for visual field testing in glaucoma.
Advertisement
Episodes in this series
Advertisement
Related to this article
June brings FDA clearance for Lumvoa, key retina and glaucoma trials, device deals, and hard truths on AI performance in eye care.
Offline smartphone AI fundus screening detects diabetic retinopathy, glaucoma, and macular degeneration in one capture, delivering high accuracy for low-resource eye care.
A large real-world cohort study finds OSA is associated with elevated glaucoma risk, though whether positive airway pressure therapy itself plays a role remains unclear.
Bayer acquired Perfuse Therapeutics and its experimental endothelin-blocking eye implant PER-001, and partnered with AI firm Iambic Therapeutics to accelerate small molecule drug discovery.
A retrospective study finds that direct selective laser trabeculoplasty significantly lowers intraocular pressure, with the greatest benefit seen in treatment-naive eyes.
Advertisement
Advertisement
Trending on Eye Care Network - Ophthalmology Times
1
AAO 2026: Optogenetic gene therapy heads to phase 2 trial in geographic atrophy
2
AAO 2026: DAYBREAK shows tarcocimab and tabirafusp-ted noninferior to aflibercept in wet AMD
3
AAO 2026: BRUNELLO 1-year results for remigromig in DME
4
Slowing Stargardt: What a 36% reduction in lesion growth could mean for adolescent patients
5